keyword
MENU ▼
Read by QxMD icon Read
search

Neuropsychiatric symptoms of dementia

keyword
https://www.readbyqxmd.com/read/28738363/mild-cognitive-impairment-and-driving-cessation-a-3-year-longitudinal-study
#1
Michael H Connors, David Ames, Michael Woodward, Henry Brodaty
BACKGROUND/AIMS: Driving cessation is associated with significant morbidity in older people. People with mild cognitive impairment (MCI) may be at particular risk of this. Very little research has examined driving in this population. Given this, we sought to identify predictors of driving cessation in people with MCI. METHODS: One hundred and eighty-five people with MCI were recruited from 9 memory clinics around Australia. People with MCI and their carers reported their driving status and completed measures of cognition, function, neuropsychiatric symptoms, and medication use at regular intervals over a 3-year period...
July 22, 2017: Dementia and Geriatric Cognitive Disorders
https://www.readbyqxmd.com/read/28735797/characteristics-correlates-and-assessment-of-psychosis-in-parkinson-disease-without-dementia
#2
Matthew J Barrett, Mark E Smolkin, Joseph L Flanigan, Binit B Shah, Madaline B Harrison, Scott A Sperling
INTRODUCTION: Considering that psychosis in Parkinson disease (PD) is associated with worse outcomes, including dementia, we aimed to study the characteristics, correlates, and assessment of PD psychosis in those without dementia. METHODS: 101 PD subjects without dementia (Montreal Cognitive Assessment ≥21/30) were recruited to participate in a study of neuropsychiatric symptoms in PD. This study included a baseline standard neurological exam and common PD symptom assessments...
July 15, 2017: Parkinsonism & related Disorders
https://www.readbyqxmd.com/read/28733181/caring-for-a-person-with-dementia-on-the-margins-of-long-term-care-a-perspective-on-burden-from-8-european-countries
#3
Caroline Sutcliffe, Clarissa Giebel, Michel Bleijlevens, Connie Lethin, Minna Stolt, Kai Saks, Maria E Soto, Gabriele Meyer, Adelaida Zabalegui, Helen Chester, David Challis
OBJECTIVES: To explore associations between carer burden and characteristics of (1) the informal carer, (2) the person with dementia, and (3) the care support network in 8 European countries. DESIGN: Cross-sectional study. SETTING: People with dementia judged at risk of admission to long-term care (LTC) facilities in 8 European countries (Estonia, Finland, France, Germany, Netherlands, Spain, Sweden, United Kingdom). PARTICIPANTS: A total of 1223 people with dementia supported by community services at home or receiving day care or respite care and their informal carers...
July 18, 2017: Journal of the American Medical Directors Association
https://www.readbyqxmd.com/read/28724467/differential-associations-between-sensory-loss-and-neuropsychiatric-symptoms-in-adults-with-and-without-a-neurocognitive-disorder
#4
Kim M Kiely, Moyra E Mortby, Kaarin J Anstey
BACKGROUND: To investigate the differential associations between sensory loss and neuropsychiatric symptoms among older adults with and without diagnosed neurocognitive disorder. METHODS: The sample comprised 1,393 adults (52.3% men) aged between 72 and 79 years from a community-based cohort study. There were 213 cases of mild and 64 cases of major neurocognitive disorders. The main outcome was number of informant reported symptoms on the Neuropsychiatric Inventory (NPI)...
July 20, 2017: International Psychogeriatrics
https://www.readbyqxmd.com/read/28724358/quality-of-care-and-quality-of-life-of-people-with-dementia-living-at-green-care-farms-a-cross-sectional-study
#5
Bram de Boer, Jan P H Hamers, Sandra M G Zwakhalen, Frans E S Tan, Hilde Verbeek
BACKGROUND: Many countries are introducing smaller, more home-like care facilities that represent a radically new approach to nursing home care for people with dementia. The green care farm is a new type of nursing home developed in the Netherlands. The goal of this study was to compare quality of care, quality of life and related outcomes in green care farms, regular small-scale living facilities and traditional nursing homes for people with dementia. METHODS: A cross-sectional design was used...
July 19, 2017: BMC Geriatrics
https://www.readbyqxmd.com/read/28701494/loss-of-phosphodiesterase-4-in-parkinson-disease-relevance-to-cognitive-deficits
#6
Flavia Niccolini, Heather Wilson, Gennaro Pagano, Christopher Coello, Mitul A Mehta, Graham E Searle, Roger N Gunn, Eugenii A Rabiner, Thomas Foltynie, Marios Politis
OBJECTIVE: To assess in vivo the expression of phosphodiesterase 4 (PDE4) and its relevance to cognitive symptoms in patients with Parkinson disease (PD) using [(11)C]rolipram PET. METHODS: We studied 12 levodopa-treated patients with PD with no concurrent diagnosis of mild cognitive impairment or dementia. Their data were compared with those from 12 healthy controls. All participants underwent neuropsychiatric and cognitive assessment using the Cambridge Neuropsychological Test Automated Battery...
July 12, 2017: Neurology
https://www.readbyqxmd.com/read/28698646/plasma-biomarkers-are-associated-with-agitation-and-regional-brain-atrophy-in-alzheimer-s-disease
#7
Jung-Lung Hsu, Wei-Ju Lee, Yi-Chu Liao, Jiing-Feng Lirng, Shuu-Jiun Wang, Jong-Ling Fuh
This study investigated the relationships among plasma biomarkers, regional brain atrophy, and clinical symptoms in patients with Alzheimer's disease (AD; n = 177), mild cognitive impairment (MCI; N = 60) and controls (n = 108). The Mini-Mental Status Examination (MMSE), Clinical Dementia Rating (CDR), and Neuropsychiatric Inventory (NPI) subscales were administered to subjects. Magnetic resonance imaging was performed and medial temporal atrophy (MTA) and posterior atrophy (PA) were assessed visually...
July 11, 2017: Scientific Reports
https://www.readbyqxmd.com/read/28689508/social-inappropriateness-in-neurodegenerative-disorders
#8
Philippe Desmarais, Krista L Lanctôt, Mario Masellis, Sandra E Black, Nathan Herrmann
BACKGROUND: New onset of mood and behavioral changes in middle-aged patients are frequently the first manifestations of an unrecognized neurocognitive disorder. Impairment of social cognition, the cognitive ability to process social information coming from others, such as emotions, to attribute mental states to others, and to respond appropriately to them, is often at the origin of behavioral manifestations in neurodegenerative disorders. METHODS: This paper reviews the current literature on social cognition impairment in neurocognitive disorders, particularly in prodromal stages of behavioral-variant frontotemporal dementia (bvFTD), Alzheimer's disease (AD), idiopathic Parkinson's disease (IPD), and Lewy body dementia (LBD)...
July 10, 2017: International Psychogeriatrics
https://www.readbyqxmd.com/read/28689190/intermediate-c9orf72-alleles-in-neurological-disorders-does-size-really-matter
#9
REVIEW
Adeline S L Ng, Eng-King Tan
C9orf72 repeat expansions is a major cause of familial frontotemporal dementia (FTD) and amyotrophic lateral sclerosis (ALS) worldwide. Sizes of <20 hexanucleotide repeats are observed in controls, while up to thousands associate with disease. Intermediate C9orf72 repeat lengths, however, remain uncertain. We systematically reviewed the role of intermediate C9orf72 alleles in C9orf72-related neurological disorders. We identified 49 studies with adequate available data on normal or intermediate C9orf72 repeat length, involving subjects with FTD, ALS, Parkinson's disease (PD), atypical parkinsonism, Alzheimer's disease (AD) and other aetiologies...
July 8, 2017: Journal of Medical Genetics
https://www.readbyqxmd.com/read/28682528/s-adenosylmethionine-same-for-neuropsychiatric-disorders-a-clinician-oriented-review-of-research
#10
REVIEW
Anup Sharma, Patricia Gerbarg, Teodoro Bottiglieri, Lila Massoumi, Linda L Carpenter, Helen Lavretsky, Philip R Muskin, Richard P Brown, David Mischoulon
OBJECTIVE: A systematic review on S-adenosylmethionine (SAMe) for treatment of neuropsychiatric conditions and comorbid medical conditions. DATA SOURCES: Searches were conducted in PubMed, EMBASE, PsycINFO, Cochrane Library, CINAHL, and Google Scholar databases between July 15, 2015, and September 28, 2016, by combining search terms for SAMe (s-adenosyl methionine or s-adenosyl-l-methionine) with terms for relevant disease states (major depressive disorder, MDD, depression, perinatal depression, human immunodeficiency virus, HIV, Parkinson's, Alzheimer's, dementia, anxiety, schizophrenia, psychotic, 22q11...
June 2017: Journal of Clinical Psychiatry
https://www.readbyqxmd.com/read/28682462/need-to-recalibrate-research-outcomes-in-alzheimer-s-disease-focus-on-neuropsychiatric-symptoms
#11
Marco Canevelli, Matteo Cesari, Flaminia Lucchini, Martina Valletta, Michele Sabino, Eleonora Lacorte, Nicola Vanacore, Giuseppe Bruno
OBJECTIVES: To determine whether neuropsychiatric symptoms (NPSs) are adequately considered in clinical research on Alzheimer's disease (AD). DESIGN: Systematic review. SETTING: Randomized controlled trials (RCTs) recruiting individuals with AD and published during the last 10 years in 16 major general medicine, neurology, psychiatry, and geriatric psychiatry journals and RCTs registered on clinicaltrials.gov and currently enrolling individuals with AD...
July 6, 2017: Journal of the American Geriatrics Society
https://www.readbyqxmd.com/read/28670272/behavioral-and-psychological-symptoms-impact-clinical-competence-in-alzheimer-s-disease
#12
Elodie Bertrand, Eelco van Duinkerken, J Landeira-Fernandez, Marcia C N Dourado, Raquel L Santos, Jerson Laks, Daniel C Mograbi
Decision-making is considered a fundamental aspect of personal autonomy and can be affected in psychiatric and neurologic diseases. It has been shown that cognitive deficits in dementia impact negatively on decision-making. Moreover, studies highlighted impaired clinical competence in neuropsychiatric disorders, such as schizophrenia and bipolar disorder. In this context, the current study explored the relationship between behavioral and psychological symptoms of dementia (BPSD) and clinical competence, especially the capacity to consent to treatment, in Alzheimer's disease (AD)...
2017: Frontiers in Aging Neuroscience
https://www.readbyqxmd.com/read/28669575/targeted-interdisciplinary-model-for-evaluation-and-treatment-of-neuropsychiatric-symptoms-a-cluster-randomized-controlled-trial
#13
Bjørn Lichtwarck, Geir Selbaek, Øyvind Kirkevold, Anne Marie Mork Rokstad, Jūratė Šaltytė Benth, Jonas Christoffer Lindstrøm, Sverre Bergh
OBJECTIVE: To determine the effectiveness of the Targeted Interdisciplinary Model for Evaluation and Treatment of Neuropsychiatric Symptoms (TIME) for treatment of moderate to severe agitation in people with dementia. METHODS: In a single-blinded, cluster randomized controlled trial in 33 nursing homes (clusters) from 20 municipalities in Norway, 229 patients (104 patients in 17 nursing homes and 125 patients in 16 nursing homes) were randomized to an intervention or control group, respectively...
June 1, 2017: American Journal of Geriatric Psychiatry
https://www.readbyqxmd.com/read/28668664/a-pilot-randomized-trial-of-a-companion-robot-for-people-with-dementia-living-in-the-community
#14
Amy Liang, Isabell Piroth, Hayley Robinson, Bruce MacDonald, Mark Fisher, Urs M Nater, Nadine Skoluda, Elizabeth Broadbent
OBJECTIVES: To investigate the affective, social, behavioral, and physiological effects of the companion robot Paro for people with dementia in both a day care center and a home setting. DESIGN: A pilot block randomized controlled trial over 12 weeks. Participants were randomized to the intervention (Paro) or control condition (standard care). SETTING: Two dementia day care centers and participants' homes in Auckland, New Zealand. PARTICIPANTS: Thirty dyads (consisting of a care recipient with dementia and their caregiver) took part in this study...
June 28, 2017: Journal of the American Medical Directors Association
https://www.readbyqxmd.com/read/28662127/core-outcome-measures-for-interventions-to-prevent-or-slow-the-progress-of-dementia-for-people-living-with-mild-to-moderate-dementia-systematic-review-and-consensus-recommendations
#15
Lucy Webster, Derek Groskreutz, Anna Grinbergs-Saull, Rob Howard, John T O'Brien, Gail Mountain, Sube Banerjee, Bob Woods, Robert Perneczky, Louise Lafortune, Charlotte Roberts, Jenny McCleery, James Pickett, Frances Bunn, David Challis, Georgina Charlesworth, Katie Featherstone, Chris Fox, Claire Goodman, Roy Jones, Sarah Lamb, Esme Moniz-Cook, Justine Schneider, Sasha Shepperd, Claire Surr, Jo Thompson-Coon, Clive Ballard, Carol Brayne, Alistair Burns, Linda Clare, Peter Garrard, Patrick Kehoe, Peter Passmore, Clive Holmes, Ian Maidment, Louise Robinson, Gill Livingston
BACKGROUND: There are no disease-modifying treatments for dementia. There is also no consensus on disease modifying outcomes. We aimed to produce the first evidence-based consensus on core outcome measures for trials of disease modification in mild-to-moderate dementia. METHODS AND FINDINGS: We defined disease-modification interventions as those aiming to change the underlying pathology. We systematically searched electronic databases and previous systematic reviews for published and ongoing trials of disease-modifying treatments in mild-to-moderate dementia...
2017: PloS One
https://www.readbyqxmd.com/read/28645127/-high-prevalence-of-antipsychotic-medication-use-in-dementia-patients-in-german-neuropsychiatric-practices
#16
Jens Bohlken, Anke Booker, Karel Kostev
Background The aim of the present study was to examine inpatients as well as patients living at home with respect to the frequency of antipsychotic medication use and to determine the factors leading to initial use of antipsychotics following dementia diagnosis. Methods This study included patients aged 60 years and over with an initial diagnosis of all-cause dementia (index date) by German psychiatrists in Disease Analyzer database (IMS Health). The main outcome measure was the proportion of patients who initially received an antipsychotic prescription after the index date...
June 2017: Fortschritte der Neurologie-Psychiatrie
https://www.readbyqxmd.com/read/28638598/caregiver-burden-is-increased-in-parkinson-s-disease-with-mild-cognitive-impairment-pd-mci
#17
Ann J Jones, Roeline G Kuijer, Leslie Livingston, Daniel Myall, Kyla Horne, Michael MacAskill, Toni Pitcher, Paul T Barrett, Tim J Anderson, John C Dalrymple-Alford
BACKGROUND: There is limited evidence on caregiver outcomes associated with mild cognitive impairment in patients with Parkinson's disease (PD-MCI) and the coping strategies used by these caregivers. METHODS: To investigate this relationship, we examined levels of burden, depression, anxiety, coping strategies and positive aspects of caregiving in the informal caregivers of 96 PD patients. The PD patients were classified using MDS-Task Force Level II criteria as showing either normal cognition (PD-N; n = 51), PD-MCI (n = 30) or with dementia (PDD; n = 15)...
2017: Translational Neurodegeneration
https://www.readbyqxmd.com/read/28632038/spatial-navigation-deficits-in-amnestic-mild-cognitive-impairment-with-neuropsychiatric-comorbidity
#18
Roxanne C Keynejad, Hana Marková, Kamila Šiffelová, Naveen Kumar, Kamil Vlček, Jan Laczó, Ellen M Migo, Jakub Hort, Michael D Kopelman
AIMS: To find out whether neuropsychiatric comorbidity (comMCI) influences spatial navigation performance in amnestic mild cognitive impairment (aMCI). METHODS: We recruited aMCI patients with (n = 21) and without (n = 21) neuropsychiatric comorbidity or alcohol abuse, matched for global cognitive impairment and cognitively healthy elderly participants (HE, n = 22). They completed the Mini-Mental State Examination and a virtual Hidden Goal Task in egocentric, allocentric, and delayed recall subtests...
February 28, 2017: Neuropsychology, Development, and Cognition. Section B, Aging, Neuropsychology and Cognition
https://www.readbyqxmd.com/read/28631194/the-use-of-cannabinoids-in-treating-dementia
#19
REVIEW
Megan Weier, Wayne Hall
PURPOSE OF REVIEW: To review and summarise the current evidence on the safety and efficacy of using cannabinoids to treat behavioural and neuropsychiatric symptoms of dementia. RECENT FINDINGS: Two randomised controlled trials testing a synthetic form of tetrahydrocannabinol have shown that while well tolerated, there was no significant therapeutic effect, based on changes to scores on the neuropsychiatric inventory (NPI). Case reports and open label trials have indicated that there may be some therapeutic benefit of adding synthetic cannabinoids as an adjunctive therapy to reduce agitation, aberrant motor behaviour and nighttime behaviour...
August 2017: Current Neurology and Neuroscience Reports
https://www.readbyqxmd.com/read/28629482/dementia-care-mapping-in-long-term-care-settings-a-systematic-review-of-the-evidence
#20
Ana Barbosa, Kathryn Lord, Alan Blighe, Gail Mountain
BACKGROUND: This systematic review identifies and reports the extent and nature of evidence to support the use of Dementia Care Mapping as an intervention in care settings. METHODS: The review was limited to studies that used Dementia Care Mapping as an intervention and included outcomes involving either care workers and/or people living with dementia. Searches were conducted in PubMed, Web of Knowledge, CINAHL, PsychINFO, EBSCO, and Scopus and manually from identified articles reference lists...
June 20, 2017: International Psychogeriatrics
keyword
keyword
76223
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"